Dx&Vx said Tuesday that it is launching a genomic big data provision service to start a full-fledged medical data business.

Based on its genomic analysis database of 440,000 cases, the largest in Korea, Dx&Vx explained that it provides anonymized clinical genomic data to companies and research institutions that require genomic big data.

Specifically, it provides clinical big data for medical diagnosis categorized by various criteria such as age, gender, year, region, and test method through its medical information database.

According to Dx&Vx, the medical information provided includes clinical analysis data on healthy people, patient groups, and those with rare diseases. They also contain genomic information on embryos, amniotic fluid cells, and newborns under one year old.

Through the results extracted through big data, the company expects it will discover biomarkers necessary for developing new drugs to treat rare diseases and cancer, secure data necessary for the drug development process, and secure core data for developing customized therapies.

"Genomic big data contains vast genomic information of patient groups and general medical information. So, it will be valuable data for new drug development companies that need information on targeted disease groups," a company official said. "Starting with this genomic big data service business, we will continue to secure verified medical data and expand collaboration with various global IT companies."